China-based startups Infinite Brain Technologies (IBT) and ATLATL Innovation Centre (ATLATL) have entered a Memorandum of Understanding (MoU), under which the two organisations will join forces to advance the field of brain health technology integrated with artificial intelligence.

IBT Global is a rising player in Digital Therapeutics (DTx) with an experienced cross-functional team operating at the intersection of neuroscience and software technology. IBT Global develops patient-facing software applications that provide better outcomes for patients with proven clinical benefit.

By collaborating with leading biopharmaceuticals, ATLATL integrates global resources to stimulate innovative developments. ATLATL currently has R&D platforms all around the world, including Beijing, Shanghai, Singapore and Boston, etc.

CEO of ATLATL, PC Zhu, expressed how ATLATL aims to make a significant contribution to the global brain health industry: “ATLATL is known for its infrastructure and operational management, specialised core facilities and on-site interactive research services. IBT is widely acknowledged for its ability to develop accurate digital therapeutics using advanced AI technologies and we are honored to work with IBT to enhance global innovation in brain health.”

Justin Jia, CTO of IBT and CEO of IBT Global said: “We are thrilled to partner with ATLATL, leveraging its extensive R&D services and vast bio-tech networks, as we at IBT work towards our mission of creating cutting-edge AI-powered digital therapeutics. Our goal is to provide effective clinical solutions for individuals battling mental disorders.”